Spinal cord injury treatment being developed using Nextim Plc’s NBS technology
02 November 2016
- Abstract presented at 8th International Symposium on Navigated Brain Stimulation in Neurosurgery and Neuromodulation -
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or the "Company"), a medical technology company with a pioneering navigated non-invasive brain stimulation system, notes recent findings announced at the 8th International Symposium on Navigated Brain Stimulation in Neurosurgery and Neuromodulation in Berlin, in which navigated transcranial magnetic stimulation (nTMS) with Nexstim’s Navigated Brain Stimulation (NBS) system demonstrated therapeutic advances for incomplete chronic spinal cord injury patients.
Researchers at the Helsinki University Hospital in Finland have developed a novel protocol for paired associative stimulation, a technique where nTMS is synchronised with peripheral nerve electrical stimulation as a long-term treatment for spinal cord injury patients. In September 2016, Science & Technology published an article titled ‘New life to paralysed muscles’ outlining how the combination of navigated transcranial magnetic stimulation and simultaneous peripheral nerve stimulation showed therapeutic potential in two patients (available here).
The NBS system was developed for pre-surgical mapping - where it has both CE mark and FDA 510k clearance - is also being used by researchers at Helsinki University for other indications including chronic pain, tinnitus and depression. Therapy utilising the NBS System for chronic spinal cord injury is a research utility and the System has not yet been approved for this therapeutic indication. See About Nexstim Plc for the approved indications for Nexstim products.
Henri Hannula, VP Sales Europe, Nexstim, commented: “Expanding use of Nexstim’s NBS systems across multiple indications demonstrates the adaptability and quality of our advanced systems. Our leading navigated transcranial magnetic stimulation technology has the potential to now make a very real difference to patients with highly challenging spinal cord injuries. As in previous years, the NBS symposium continues to attract increasing numbers of participants discussing protocols and sharing best practice in demonstrations and presentations.”
Martin Jamieson, Chairman & CEO
Further information is available on the website www.nexstim.com or by telephone:
Martin Jamieson, Chairman & CEO firstname.lastname@example.org
UB Securities Oy (Certified Adviser) +358 (0)9 2538 0246
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Laura Thornton email@example.com
About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com
About Transcranial Magnetic Stimulation (TMS)
TMS uses an induction coil in which a time-varying magnetic field is generated to induce an electric E-field within the brain. The neurons at the locations of the brain exposed to a strong enough E-field will become activated, or stimulated. In NBS, the E-field induced in the brain by a TMS induction coil device is shown as an overlay on a graphical display of an anatomical representation of the subject's brain. By viewing the display, a user can visualize the E-field and, therefore, interactively position the TMS coil device, in real time, in relation to the brain to stimulate a target site. The response from the stimulation is measured with an integrated EMG to accurately record the size and latencies MEP caused by the stimulation. To accurately personalize the dose level to each individual the motor threshold needs to be obtained. Optimizing E-field generation and individually defining response level an optimal stimulation dose can be accurately and repeatedly administered.
Spinal cord injury treatment being developed using Nextim Plc’s NBS technology - Press release 2.Nov.2016.pdf
Back to Press Releases